What they found: No serious adverse events triggered by AOD-9604 The most frequent side effects: headache (~5 %), occasional fatigue, at the same frequency as placebo No changes in IGF-1 levels, glycemia, blood pressure, heart rate No signals of cardiovascular, hepatic or renal toxicity Safety profile comparable to placebo Why it matters: From a safety perspective, AOD-9604 is one of the safest peptides in the clinical registry
However, pancreatitis survivors require individualized assessment because underlying pancreatic vulnerability or metabolic patterns may warrant extra caution
Working with a provider also helps ensure that you stay on top of your body composition, so you realize quickly if you start to gain weight
Some studies have indicated that it can improve brain function and protect us from potential damage to our brain cells
A control experiment verified that tirzepatide itself did not affect place conditioning when vehicle was paired with both compartments (t 14 =0.49, P=0.631
GLP-1 therapy can be effective when hormonal and metabolic shifts are the main drivers of the weight gain